CTLA-4 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2548-2553

  Deng, Lijing ^a   Zhou, Haixia ^a   Yang, Jing ^a   Xiao, Jun ^a   Wang, Bo ^a   Wang, Lan ^a   Ou, Xuemei ^a   Feng, Yulin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; CTLA 4; Polymorphisms

Indexed keywords

CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

AGED; ARTICLE; CASE CONTROL STUDY; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CTLA-4; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; POLYMORPHISMS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; VITAL CAPACITY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CTLA-4; POLYMORPHISMS;

AGED; CASE-CONTROL STUDIES; CHINA; CTLA-4 ANTIGEN; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; VITAL CAPACITY;

EID: 84887110856     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zhu G, Agusti A, Gulsvik A, Bakke P, Coxson H, Lomas DA, Silverman EK and Pillai SG. CTLA4 gene polymorphisms are associated with chronic bronchitis. Eur Respir J 2009;34:598-604.
2. Gu LQ, Zhu W, Zhao SX, Zhao L, Zhang MJ, Cui B, Song HD, Ning G and Zhao YJ. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. Clin Endocrinol (Oxf) 2010;72:248-255.
3. Azizi E, Massoud A, Amirzargar AA, Mahmoudi M, Soleimanifar N, Rezaei N, Jamshidi AR, Nikbin B and Nicknam MH. Association of CTLA4 gene polymorphism in Iranian patients with ankylosing spondylitis. J Clin Immunol 2010;30:268-271.
4. Chong KK, Chiang SW, Wong GW, Tam PO, Ng TK, Hu YJ, Yam GH, Lam DS and Pang CP. Association of CTLA-4 and IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in Chinese children. Invest Ophthalmol Vis Sci 2008;49:2409-2415.
5. Douroudis K, Laine AP, Heinonen M, Hermann R, Lipponen K, Veijola R, Simell O, Knip M, Uibo R, Ilonen J and Kisand K. Association of CTLA4 but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates. Hum Immunol 2009;70:536-539.
6. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C and Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
7. Cookson WO. State of the art. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:473-475.
8. Murray CJ and Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science 1996;274:740-743.
9. Turato G, Zuin R and Saetta M. Pathogenesis and pathology of COPD. Respiration 2001;68:117-128.
10. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB and Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science 1998;282:2263-2266.
11. Sperling AI and Bluestone JA. The complexities of T-cell co-stimulation:CD28 and beyond. Immunol Rev 1996;153:155-182.
12. Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE and Weiss ST. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002;70:1229-1239.
13. Malhotra A, Peiffer AP, Ryujin DT, Elsner T, Kanner RE, Leppert MF and Hasstedt SJ. Further evidence for the role of genes on chromosome 2 and chromosome 5 in the inheritance of pulmonary function. Am J Respir Crit Care Med 2003;168:556-561.
14. Pauwels RA, Buist AS, Ma P, Jenkins CR and Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD):executive summary. Respir Care 2001;46:798-825.
15. GOLD Executive Committee. Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (Updated 2011). http://www.goldcopd.org/.
16. Liu Y, Liang WB, Gao LB, Pan XM, Chen TY, Wang YY, Xue H, Zhang LS and Zhang L. CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Hum Immunol 2010;71:1141-1146.
17. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N, Loewenthal R, Nagler A and Cohen Y. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008;32:421-427.
18. Caramori G and Adcock I. Gene-environment interactions in the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2006;6:323-328.
19. Steinman L. State of the art. Four easy pieces:interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. Proc Am Thorac Soc 2006;3:484-486.
20. Immune boosters. Curcumin and the immune system. TreatmentUpdate 2000;11:7.
21. Perez-Garcia A, De la Camara R, Roman-Gomez J, Jimenez-Velasco A, Encuentra M, Nieto JB, de la Rubia J, Urbano-Ispizua A, Brunet S, Iriondo A, Gonzalez M, Serrano D, Espigado I, Solano C, Ribera JM, Pujal JM, Hoyos M and Gallardo D. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 2007;110:461-467.
22. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML and DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-6611.
23. Fernandez-Mestre M, Sanchez K, Balbas O, Gendzekhzadze K, Ogando V, Cabrera M and Layrisse Z. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. Hum Immunol 2009;70:532-535.
24. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, Shi Y, Yao J, Guo Y, Yu D, Tian T, Zhou X, Shen H and Lin D. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008;68:7025-7034.
25. Teutsch SM, Booth DR, Bennetts BH, Heard RN and Stewart GJ. Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. J Neuroimmunol 2004;148:218-230.
26. Knight AK, Serrano D, Tomer Y and Cunningham-Rundles C. CTLA-4 gene exon-1 +49 A/G polymorphism:lack of association with autoimmune disease in patients with common variable immune deficiency. J Clin Immunol 2007;27:95-100.